Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Experimental studies using OMV in a new platform do SARS-CoV-2 vaccines

Full text
Author(s):
Gaspar, Emanuelle B. [1] ; Prudencio, Carlos Roberto [2] ; De Gaspari, Elizabeth [2]
Total Authors: 3
Affiliation:
[1] Embrapa Southern Reg Anim Husb, Anim Hlth Dept, Bage - Brazil
[2] Adolfo Lutz Inst, Dept Immunol, Sao Paulo - Brazil
Total Affiliations: 2
Document type: Journal article
Source: HUMAN VACCINES & IMMUNOTHERAPEUTICS; v. 17, n. 9, p. 2965-2968, SEP 2 2021.
Web of Science Citations: 1
Abstract

Although COVID-19 vaccines have recently been approved for emergency use, search for new vaccines are still urgent, since the access of the countries, especially the poorest, to the vaccines, has shown to be slower than the necessary to rapidly control the pandemic. We proposed a novel platform for vaccine using recombinant receptor binding domain (rRBD) from Sars-Cov-2 spike protein and Neisseria meningitidis outer membrane vesicles (OMVs). The antigen preparation produced a humoral and cellular immune response. Taken together our findings suggest a good immunostimulatory patter in response to immunization with rRBD plus N. meningitidis OMV. (AU)

FAPESP's process: 18/04202-0 - Study of the immunogenicity of outer membrane antigens of Neisseria meningitidis and interaction with cationic lipids: evaluation of new adjuvant for Neisseria meningitidis in different strains of elderly mice
Grantee:Elizabeth Natal de Gaspari
Support Opportunities: Regular Research Grants
FAPESP's process: 12/15568-0 - Study of the immunogenicity of outer membrane antigens of Neisseria meningitidis and interaction with cationic lipids: evaluation of different immunization schedules in different strains of mice
Grantee:Elizabeth Natal de Gaspari
Support Opportunities: Regular Research Grants